Evaluation of antibiotic resistance to orally administrable antibiotics in staphylococcal bone and joint infections in one of the largest university hospitals in Germany: is there a role for fusidic acid?

• Published in: International journal of antimicrobial agents Vol. 47; no. 2; pp. 155 - 157
• Main Authors: Klein, Sabrina, Nurjadi, Dennis, Eigenbrod, Tatjana, Bode, Konrad A
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.02.2016
• Subjects: Administration, Oral; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Antibiotic therapy; Biofilm; Coagulase-negative staphylococci; Drug Resistance, Bacterial; Fusidic acid; Fusidic Acid - pharmacology; Fusidic Acid - therapeutic use; Germany; Hospitals, University; Humans; Infectious Disease; Osteoarthritis - microbiology; Prosthetic infection; Staphylococcal Infections - microbiology; Staphylococcus - drug effects; Staphylococcus - isolation & purification; Staphylococcus aureus; Biofilm; Fusidic acid; Prosthetic infection; Staphylococcus aureus; Coagulase-negative staphylococci; Antibiotic therapy
• ISSN: 0924-8579; 1872-7913
• DOI: 10.1016/j.ijantimicag.2015.12.002

Highlights • Resistance to commonly used oral antibiotics to treat staphylococcal bone and joint infections (BJIs) is increasing. • 75% of MRSA and ca. 50% of CoNS causing BJIs were resistant to the commonly used combinations (rifampicin and fluoroquinolone or clindamycin). • 87% of rifampicin-resistant MRSA strains and 62% of rifampicin-resistant CoNS were susceptible to fusidic acid. • Fusidic acid should be considered as an alternative/option for rifampicin, especially since this drug is recommended in official guidelines and is available as an oral agent in some European countries.